Targeted drug combination for cells infected by viruses
The current corona pandemic shows the importance of antiviral drugs. A project funded by the LOEWE Exploration now explores a concept to develop antiviral agents with lower side effects. ‘A critical aspect in drug discovery is the relationship between the desired effect and possible side effects, explains Professor Felix Hausch from the TU Darmstadt. Together with his colleague professor Eberhard Hildt from the Paul Ehrlich Institute, he explores, whether the combination of two prominent types of antiviral drugs can be used to derive so-called prodrugs that preferentially act in virally infected cells. This could reduce undesirable effects in unaffected cells of patients. This concept of so-called protease-activatable antiviral prodrugs will be demonstrated using hepatitis C viruses (HCV) and corona viruses (SARS-CoV2) as well-understood model systems.
We would like to customise the information and usability of this website to your preferences and needs.
To this end, we use so-called cookies. Please choose which cookies you would like to enable when visiting our webpages.
Some of these cookies are required to load and correctly display this website on your device.
These are strictly necessary or essential cookies and cannot be deselected.
The preferences cookie saves your language setting, while the statistics cookie regulates
how the open-source statistical software “Matomo” analyses your visits to and activities on our website.
For more information about cookies we use, please refer to our